201 related articles for article (PubMed ID: 38284393)
1. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review.
Ardekani ZM; Lorenzo-Leal AL; Bach H
Nanomedicine (Lond); 2024 Jan; 19(2):163-179. PubMed ID: 38284393
[No Abstract] [Full Text] [Related]
2. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
Chen F; Liu Q; Xiong Y; Xu L
Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.
Takedatsu H; Mitsuyama K; Torimura T
World J Gastroenterol; 2015 Oct; 21(40):11343-52. PubMed ID: 26525603
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
5. An Update on Herbal Products for the Management of Inflammatory Bowel Disease.
Arya H; Dass R; Chopra B; Kriplani P; Deswal G; Singh Grewal A; Dhingra AK; Kumar S
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(1):1-9. PubMed ID: 37497699
[TBL] [Abstract][Full Text] [Related]
6. Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.
Bhat MA; Usman I; Dhaneshwar S
Curr Rev Clin Exp Pharmacol; 2024; 19(3):234-249. PubMed ID: 37859409
[TBL] [Abstract][Full Text] [Related]
7. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
[TBL] [Abstract][Full Text] [Related]
8. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
[TBL] [Abstract][Full Text] [Related]
9. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
10. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.
Le Berre C; Loy L; Lönnfors S; Avedano L; Piovani D
World J Gastroenterol; 2020 Aug; 26(29):4343-4355. PubMed ID: 32848338
[TBL] [Abstract][Full Text] [Related]
11. Pathological features-based targeted delivery strategies in IBD therapy: A mini review.
Li S; Zhang F; Zhang Q
Biomed Pharmacother; 2022 Jul; 151():113079. PubMed ID: 35605297
[TBL] [Abstract][Full Text] [Related]
12. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.
Pichai MV; Ferguson LR
World J Gastroenterol; 2012 Jun; 18(23):2895-901. PubMed ID: 22736912
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
14. Phytochemicals and their potential usefulness in inflammatory bowel disease.
Somani SJ; Modi KP; Majumdar AS; Sadarani BN
Phytother Res; 2015 Mar; 29(3):339-50. PubMed ID: 25572840
[TBL] [Abstract][Full Text] [Related]
15. Review of Saccharomyces boulardii as a treatment option in IBD.
Sivananthan K; Petersen AM
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
[TBL] [Abstract][Full Text] [Related]
16. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
Kirsner JB
Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management.
D'Arcangelo G; Aloi M
Paediatr Drugs; 2017 Apr; 19(2):113-120. PubMed ID: 28150131
[TBL] [Abstract][Full Text] [Related]
19. The Prevalence of Inflammatory Bowel Disease in Greenland.
Gantzel RH; Vesterdal JD; Haase AM; Petersen AJ; Grønbæk H; Pedersen ML
Inflamm Bowel Dis; 2023 Dec; 29(12):1879-1885. PubMed ID: 36702537
[TBL] [Abstract][Full Text] [Related]
20. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
